Warenkorb 0

Congratulations! Your order qualifies for free shipping Sie sind 45 kr von kostenlosem Versand entfernt.
Sorry, looks like we don't have enough of this product.

Privatkunde
Geschäftskunde
Bitte geben Sie eine gültige USt-IdNr. ein.
Subtotal Free
Shipping, taxes, and discount codes are calculated at checkout

R-alpha lipoic acid from sodium lipoate

R-Alpha-Liponsäure aus Natriumlipoat

GENERAL

  • Sulfur-containing fatty acid (with carboxyl group) and thioalcohol (with thiol group)
  • Present in mitochondria (“powerhouses” of our cells).
  • Soluble in fat and water (therefore it can cross the blood-brain barrier)
  • Endogenous synthesis is only possible in small quantities (from octanoic acid and L-cysteine)
  • Occurs as (interchangeable)
    • Dihydrolipoic acid DHLA (reduced form)
    • Lipoic acid LA (oxidized form) as well as
  • Component of the coenzymes lipoamide (oxidized) and dihydrolipoamide (reduced) à lipoamide = lipoic acid + lysine
  • S- vs. R-alpha lipoic acid: R-alpha lipoic acid (RALA) is the natural, endogenous form, while S-alpha lipoic acid is the synthetic variant. However, only R-alpha lipoic acid has health-promoting effects, whereas S-alpha lipoic acid has no function or is rather detrimental to the body, as it counteracts the positive effects of RALA and can promote insulin resistance.

BENEFITS OF R-ALPHA-LIPOIC ACID AS SODIUM LIPOATE

Ordinary R-alpha lipoic acid is very unstable and often begins to decompose into an insoluble polymer during the processing. Therefore, we use a highly purified, stabilized R-alpha lipoic acid in the form of sodium R-lipoate.

This so-called Na-RALA is significantly more bioavailable (Studies on comparable products have shown a 21-fold increased bioavailability (determined) as a simple, unstabilized R-alpha lipoic acid, as measured by the maximum blood plasma concentration (Cmax), and is also 100% free of S-alpha lipoic acid. Furthermore, unlike the potassium salt (K-RALA), the sodium salt is completely water-soluble and therefore requires no excipients.

In contrast to the production of racemic alpha-lipoic acid, the additional processing steps required for the production of Na-RALA also ensure particularly thorough purification, so that the active ingredient is ultimately free of residues.

EFFECTS

a)    Lipoic acid acts as an antioxidant (non-enzymatic antioxidant) and synergistically supports other antioxidants:

b)    Lipoic acid regenerates other antioxidants:

c)    Lipoic acid plays a central role in the body's own detoxification process:

  • Detoxification Phase I: Lipoic acid is involved in the disposal of radicals and reactive metabolites.
  • Detoxification Phase II and III (chelation): Lipoic acid complexes metals such as iron, copper, mercury, and cadmium and is involved in their elimination.

d)    Lipoic acid and cofactor effects:

  • Energy generation: Lipoic acid is a component of the coenzyme lipoamide.
    • in the pyruvate dehydrogenase complex and (PDH)
    • in the 2-oxoglutarate or α-ketoglutarate dehydrogenase complex (OGDC)
  • Amino acid metabolism: Lipoic acid is a component of the coenzyme lipoamide.
    • in the branched-chain α-ketoglutarate dehydrogenase complex (BCKDC) during the breakdown of branched-chain amino acids leucine, isoleucine and valine
    • in the glycine cleavage system (GCS) during the breakdown of glycine
    • in the 2-oxoadipate dehydrogenase complex during the degradation of lysine

INDICATIONS FOR RALA SUPPLEMENTATION

  • Radical stress in general
  • Pollutant detoxification (z.B. Heavy metal contamination
  • nervous system (z.B. Dysfunction of peripheral nerves
  • Polyneuropathy (including chemotherapy-induced CIPN)
  • Alzheimer's disease, multiple sclerosis, Down syndrome
  • Psychological stress (z.B. Stress, schizophrenia)
  • Diabetes mellitus
    • Promoting the conversion of carbohydrates into energy,
    • Promotes glucose uptake into muscle tissue,
    • Increased sensitivity of glucose to insulin
  • Cardiovascular diseases (z.B. Arteriosclerosis)
  • Eye diseases (z.B. Cataract)
  • Liver diseases (z.B. Hepatitis C)
  • Kidney dysfunction
  • aging
  • oncology
  • Obesity

POSSIBLE SIDE END & INTERACTIONS

  • 200 mg per kg of body weight is considered safe for long-term intake.
  • In isolated cases, and especially with rapid parenteral (= infusion) administration: headache, shortness of breath, nausea, stomach upset and/or diarrhea are possible.
  • Influence on thyroid function with a reduction in thyroid hormones, v.a. when T4 is administered concurrently (Source: Study Segermann J 1991: ALA reduces T4-induced T3 formation by 56%; University of Maryland: “Alpha-lipoic acid may lower levels of thyroid hormone.Blood hormone levels and thyroid function tests should be monitored closely in people taking thyroid hormones who are also taking alpha-lipoic acid")

The following interactions could appear:

  • Chelation occurs with iron, magnesium, and calcium supplements when taken simultaneously – therefore, ensure a time interval of 1-2 hours.
  • Weakening of the effect due to metal ion complex formation (z.B. Cisplatin, isoniazid, cycloserine, D-penicillamine)
  • Increased effect of insulin and oral antidiabetic drugs at very high doses (leads to a drop in blood sugar)
  • Sugar molecule complexes (z.B. Fructose, glucose and Ringer's solution)
  • Solutions that react with SH groups or disulfide bridges

Insufficient data is available regarding:

Pregnant and breastfeeding women (only under strict indication!) as well as those with serious liver and kidney diseases. Therefore, its use should always be discussed with the treating physician.

CAUSES & CONSEQUENCES OF LIPOIC ACID DEFICIENCY

Possible causes

  • Reduced intake (z.B. Nutritional deficiencies, absorption disorders)
  • Increased consumption (z.B. (in case of illness)
  • Synthesis disorder

Possible consequences

  • Cell damage
  • Diseases of the nervous system
  • Impaired glucose utilization
  • Kidney disease

DOSAGE

  • The exact lipoic acid requirement in addition to diet and endogenous synthesis is unknown and depends on many factors (such as intake, synthesis, individual situation); the u.g. Ranges are taken from the current state of research.
  • Dietary intake is insufficient for medical-therapeutic effects.
  • Bioavailability is approximately 70% when taken orally; this can be significantly increased by adding bioenhancers such as pipern.
  • Preventive dosage: 100-300 mg
  • Therapeutic dosage: 600-1200 mg